Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 3/20 | 0.56 |
| ▸ | HTR1B | P28222 | 8/20 | 0.54 |
| ▸ | HTR1A | P08908 | 8/20 | 0.54 |
| ▸ | HTR1D | P28221 | 7/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068463 | 1.00 | HTR2A (0.68) | HTR2AKMT2AMEN1HTR2CHTR1B | |
| Hydrochloric Acid SCHEMBL31534070 | 0.99 | KMT2A (0.68) | HTR2AKMT2AMEN1HTR2CHTR1B | |
| SCHEMBL2534378 | 0.89 | HTR1A (0.68) | HTR2AKMT2AHTR2CHTR1BHTR1A | |
| Hydrochloric Acid SCHEMBL21546053 | 0.87 | NPSR1 (0.68) | HTR2AKMT2AMEN1HTR2CHTR1B | |
| Hydrochloric Acid SCHEMBL31181453 | 0.87 | NPSR1 (0.68) | HTR2AKMT2AMEN1HTR2CHTR1B | |
| SCHEMBL31068472 | 0.82 | HTR6 (0.71) | HTR2AKMT2AHTR2CHTR1BHTR1A | |
| Oxalic Acid SCHEMBL2540213 | 0.82 | CYP1A2 (0.68) | HTR2AKMT2AMEN1HTR2CHTR1B | |
| SCHEMBL379337 | 0.81 | HTR2A (1.00) | HTR2AKMT2AMEN1HTR2CHTR1B | |
| SCHEMBL29874859 | 0.81 | HTR2A (1.00) | HTR2AKMT2AMEN1HTR2CHTR1B | |
| SCHEMBL2537626 | 0.78 | HTR2A (0.74) | HTR2AKMT2AMEN1HTR2CHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396191-B1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2026-02-18 | — | — | EP | disclosed |
| US-12421232-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3768267-B1 | BETA-CARBOLINE DERIVATIVES AS DYRK1A INHIBITORS FOR THE TREATMENT OF E.G. DIABETES | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250129092-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2025-04-24 | — | — | US | disclosed |
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-04-25 | — | — | US | disclosed |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2021-04-01 | — | — | US | disclosed |
| EP-3768267-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-112135613-A | Kinase inhibitor compounds and compositions and methods of use | 西奈山伊坎医学院 | 2020-12-25 | — | — | CN | disclosed |
| WO-2019183245-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-26 | — | — | WO | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, DYRK1A, CSNK1G3 | HTR2A 1534/4885KMT2A 1230/4885MEN1 1252/4885 |
| US-20250129092-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | AHR, ARNT, AIPL1 | HTR2A 655/4885KMT2A 1548/4885MEN1 4454/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | HTR2A 5/4885KMT2A 1269/4885MEN1 1889/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | HTR2A 5/4885KMT2A 1269/4885MEN1 1889/4885 |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | CSNK1A1, CSNK1E, CSNK1G3 | HTR2A 2071/4885KMT2A 1893/4885MEN1 1541/4885 |
| US-12421232-B2 | Kinase inhibitor compounds and compositions and methods of use | CSNK1A1, DYRK1A, CSNK1G3 | HTR2A 1534/4885KMT2A 1230/4885MEN1 1252/4885 |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, CSNK1E, CSNK1G3 | HTR2A 2071/4885KMT2A 1893/4885MEN1 1541/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | HTR2A 5/4885KMT2A 1269/4885MEN1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.